Four rhesus macaques were sequentially immunized with live vaccines ⌬vpu⌬nefSHIV-4 (vaccine-I) and ⌬vpu SHIV PPC (vaccine-II). The vaccine viruses did not replicate productively in the peripheral blood mononuclear cells (PBMCs) of the vaccinated animals. All four animals developed binding antibodies against both the vaccine-I and -II envelope glycoproteins but neutralizing antibodies only against vaccine-I. They developed vaccine virus-specific CTLs that also recognized homologous as well as heterologous pathogenic SHIVs. Thirty weeks after the last immunization, the vaccinated animals and three unvaccinated control animals were challenged iv with a highly virulent heterologous SHIV 89.6 P. As expected, the three unvaccinated control animals developed large numbers of infectious PBMCs, high plasma viremia, and precipitous loss of CD4 ϩ T cells. Two controls did not develop any immune response and succumbed to AIDS in about 6 months. The third control animal developed neutralizing antibodies and had a more chronic disease course, but eventually succumbed to AIDS-related complications 81 weeks after inoculation. The four vaccinated animals became infected with challenge virus as indicated by the presence of challenge virus-specific DNA in the PBMCs and RNA in plasma. However, virus in these animals replicated approximately 200-to 60,000-fold less efficiently than in control animals and eventually, plasma viral RNA became undetectable in three of the four vaccinates. The animals maintained normal CD4 ϩ T-cell levels throughout the observation period of 85 weeks after a transient drop at Week 3 postchallenge. They also maintained CTL responses throughout the observation period. These studies thus showed that the graded immunization schedule resulted in a safe and highly effective long-lasting immune response that was associated with protection against AIDS by highly pathogenic heterologous SHIV 89.6 P.
INTRODUCTION
HIV-1 is not known to induce protective immunity among any infected individuals, yet some persistently infected individuals remain healthy and develop vastly reduced virus concentrations in plasma [long-term nonprogressors (LTNP)] accompanied by humoral and cellular immune responses to the virus, including neutralizing antibodies (Cao et al., 1995; Montefiori et al., 1996; Pilgrim et al., 1997; Binley et al., 1998; Zhang et al., 1997; Carotenuto et al., 1998; Cecilia et al., 1999) and CTLs (Betts et al., 1999; Bariou et al., 1997; Pontesilli et al., 1997; Harrer et al., 1996; Pilgrim et al., 1997; Klein et al., 1995; Nehete et al., 1998; Dyer et al., 1999) . This observation suggested that an anti-HIV vaccine that can induce this type of immune response and maintain it for a prolonged period may be protective against AIDS following exposure to HIV-1. Clinical trials currently in progress are assessing the type and duration of immune responses that can be induced by recombinant proteins of the virus (Graham and Wright, 1995; Graham et al., 1996; Mascola et al., 1996; Connor et al., 1998; Corey et al., 1998) . However, in view of the tropism of the virus for the defense/immune cells of the host, and that these cells reside throughout the body, including mucosal surfaces, it is unlikely that a vaccine would prevent infection following exposure to the virus. Rather, success of the vaccine would be assessed by its ability to limit spread of the virus among the target cells and, hopefully, cause elimination of the infected cells. Since HIV causes fatal infections in humans, a comprehensive analysis of vaccine possibilities can be obtained only by use of animal models (Letvin, 1998) .
The macaque models of HIV pathogenesis using SIV and SHIV provide the best systems to assess vaccine safety and efficacy (Hirsch et al., 1995; Luciw et al., 1995; Joag et al., 1996 Joag et al., , 1997 Reimann et al., 1996a,b; Igarashi et al., 1999) . The SIV model has provided seminal information in the vaccine field. For example, this model has shown that use of inactivated virus preparations and recombinant viral proteins as vaccines were controversial, if not of equivocal value, in protection against disease ( Murphey-Corb et al., 1989; Cranage et al., 1992; Johnson et al., 1992; Langlois et al., 1992; Putkonen et al., 1993; Daniel et al., 1994) . The model has also shown that deletion of accessory genes from pathogenic SIV resulted in attenuation of the virulence of the agent and, further, that use of such attenuated viruses as vaccines resulted in induction of protection against disease caused by pathogenic strains of virus. In nearly all cases, protection was associated with development of cytotoxic antiviral CD8 ϩ T cells (Johnson et al., 1997 Joag et al., 1998a; Johnson and Desrosiers, 1998; Wyand et al., 1999) , the same type of cells seen in human HIV-infected LTNP (Harrer et al., 1996; Nehete et al., 1998) . The effectiveness of the CD8 ϩ T cells was previously proven with the demonstration that elimination of these cells from animals resulted in enhanced virus replication (Schmitz et al., 1999; Jin et al., 1999) . The major problem involving use of the gene-deleted attenuated SIV vaccine is the retention of virulence of the virus. In a recent study, live attenuated SIV, when inoculated to newborn macaques, became pathogenic (Baba et al., 1999) .
The SHIV model was developed after establishment of the SIV model but its use supported findings made using the SIV model, with the demonstration that live attenuated vaccines were highly effective in preventing disease (Joag et al., 1998a) . These live attenuated vaccines were constructed based on our observations that the two accessory genes vpu and nef were important for virulence, as evident by expression of functional Vpu protein and several changes in the nef gene in pathogenic SHIV KU that was derived from nonpathogenic SHIV-4 (McCormick-Davis et al., 1998) . Assuming that changes in the two accessory genes vpu and nef contributed to the development of a virulent virus variant, we deleted portions of both genes from the original SHIV-4 virus and designated this virus ⌬vpu⌬nefSHIV-4 (vaccine-I). We also selected another nonpathogenic virus (SHIV PPC ) and deleted 60 bp in the vpu gene and designated that as ⌬vpuSHIV PPC (vaccine-II).
Use of both SIV and SHIV vaccines showed that protection correlates with the degree of replication of the vaccine virus . The less the virus replicated, the less effective it was in eliciting protection. On the other hand, the more the vaccine virus replicates, the greater the chance that it would be pathogenic. The best vaccine would therefore be one that replicated minimally yet be highly effective in inducing protective immunity. In an earlier report, we confirmed the replication/efficacy concept with use of the two SHIV vaccines. The first vaccine, vaccine-I, replicated minimally but, although disease caused by challenge virus, SHIV KU , was delayed, five of six immunized animals eventually developed AIDS. In contrast, the second vaccine, vaccine-II, replicated robustly with demonstrable infectivity in PBMCs but without causing pathological effects. The productive infection, however, was transient. It was highly effective in preventing AIDS. All of the animals immunized with this virus became infected with the challenge virus but the challenge virus became unrecoverable from five of the six animals and all six have remained healthy for more than 3 years. Success of vaccine-II was ascribed to cellular and humoral immune responses induced by the vaccine virus during the productive phase of replication .
In the experiments described in this report, we asked whether animals immunized sequentially with vaccine-I and vaccine-II (graded immunizations) would result in reduced productive replication of vaccine-II but with the same beneficial effects of vaccine-II (complete protection against AIDS) that was associated with the productive replication of this virus when given alone. The purpose of the present study was threefold: (1) to determine whether prior immunization of macaques with vaccine-I would attenuate the replication of vaccine-II, and thus reduce the potential for the latter to become pathogenic; (2) to characterize the immune responses to the vaccine viruses and the challenge virus following immunization, but prior to challenge; and (3) to determine whether the immunized animals would resist development of AIDS following exposure to the challenge virus and, if so, whether challenge virus concentrations would decline with time, following anticipated infection at the time of exposure. We examined the cellular and humoral immune responses in four rhesus macaques after sequential immunization with vaccine-I followed by vaccine-II. These animals along with three unvaccinated control animals were challenged with highly pathogenic SHIV 89.6 P that has an envelope that is antigenically distinct from that of the vaccine viruses but shares the Gag and Pol of the latter. Challenged vaccinated and unvaccinated animals were monitored for virus replication, clinical disease, and longevity of immune responses for more than 19 months.
RESULTS

Vaccine phase
Four animals were administered vaccine-I, followed by two sequential inoculations at 4 and 7 months with vaccine-II. Infectious PBMCs were not detected at any time points in any of the animals following each of the three vaccinations. However, viral infection was established in all four animals, as determined by amplification of SIVgag in PBMC DNA by PCR showing a low level of replication that was undetectable by classical infectious cell assays. These animals did not lose CD4 ϩ T cells (data not shown). Nevertheless, prior immunization with vaccine-I was associated with reduced replication of vaccine-II.
Development of binding and neutralizing antibodies in vaccinated macaques
Plasma samples were examined for binding and neutralizing antibodies 9 weeks after the first vaccination, at two time points (Weeks 19 and 26) 3 and 10 weeks after oral inoculation with vaccine-II, and at three time points (Weeks 38, 46, and 55) beginning 10 weeks after the second vaccination with vaccine-II (Table 1) . Vaccine-I induced binding antibodies in only one of the four vaccinated animals (RPz). None developed neutralizing antibodies against the virus. Three weeks after oral inoculation with vaccine-II given at Week 16, all four animals developed binding antibodies to vaccine-I and one developed detectable antibody against vaccine-II (RPz; antibody titer 100). This response was boosted further after the third vaccination at Week 28, with development of an anamnestic response to vaccine-I. The animals also developed low titers of neutralizing antibodies to vaccine-I (peak antibody titer 20-40), but only after immunization with vaccine-II. None developed neutralizing antibodies to vaccine-II. The vaccine-I-specific antibodies did not neutralize SHIV 89.6 P that was used for challenge. SHIV , and heterologous pathogenic virus SHIV 89.6 P. The results of this experiment are shown in Fig. 1 . The effectors from all four vaccinates recognized all three viruses and lysed the targets infected with them. As expected, effectors from different macaques exhibited different degrees of lysis, of which macaque RJo was the best followed by RWg, RTt, and RPz, respectively. Generally, vaccine-II-specific lysis was highest, followed by SHIV KU-2 and SHIV 89.6 P. In view of the results that CTLs from different vaccinated animals recognized two distinct viruses that contained the envelopes from two different isolates of HIV-1, we decided to analyze whether vaccine-induced CTLs were directed against only one protein or different proteins encoded by viruses. We used the same CTL effectors and tested them against autologous B-LCL targets infected with recombinant vaccinia viruses expressing either HIV-1Env, SIV-Gag, or SIV-Pol. In another experiment, we obtained lymph node biopsies at Week 19 following the third immunization, and prepared single-cell suspensions, stimulating them in a similar manner as done for PBMC. These cells were used as lymph node effectors, to determine whether CTLs were present in secondary lymphoid tissues. The results of these experiments are illustrated in Fig. 2 . Lymph node effectors showed more pronounced lysis than that of PBMC effectors. Surprisingly, all four vaccinated macaques showed predominantly anti-Env-specific CTLs in the lymph nodes, followed by Gag and Pol. In contrast, PBMC effectors from each animal responded differently to the viral proteins, with macaque RJo showing maximum lysis against Gag, RPz against Pol, and RTt as well as RWg against Env. Interestingly, macaque RWg PBMC effectors showed lysis only against Env. However, those effectors recognized both SHIV KU and SHIV 89.6 P (Fig. 2) .
Challenge phase
Clinical outcome of SHIV 89.6 P infection in unvaccinated control animals. Thirty weeks after the third immunization, the four vaccinated and three unvaccinated animals were challenged by iv inoculation of 1 ml of undiluted SHIV 89.6 P (10,000 TCID 50 ). The three unvaccinated control animals developed highly productive infections (Figs. 3B and 3C) and lost Ͼ90% CD4 ϩ T cells within 3 weeks (Fig.  3A) . Two control animals (49/P1 and 49/P2) progressed to clinical AIDS and were euthanized at Weeks 27 and 30, respectively. The third control (52/C) developed a more chronic course of disease and succumbed to AIDSrelated complications at Week 81 postchallenge. Examination of viral burdens in these animals showed that all three had equivalent viral RNA levels of approximately 10 7 copies Eq/ml at Week 2 and 5 ϫ 10 5 -5 ϫ 10 6 between Weeks 2 and 16. However, these animals varied in numbers of infectious cells in PBMC. The two rapid progressors had much higher numbers of infectious PBMCs (1000 infected cells/10 6 PBMCs) compared to the slow progressor (10 infected cells/10 6 PBMCs) (Fig. 3C ). These data suggested that the major site of virus replication in 52/C was in cells other than PBMC, and that the free virus that was detected in real-time RT-PCR must have been transported to plasma. ϩ T-cell clones infected with vaccine-II as described under Materials and Methods. They were tested after 2 weeks of initial stimulation against control T cells and autologous HS CD4 ϩ T-cell clones infected with vaccine-II, SHIV KU-2 , and SHIV 89.6 P. The effectors were tested in a 4-h chromium release assay at E/T ratio of 80/1, 40/1, 20/1, and 10/1. The results presented here depict specific lysis at a effector/target ratio of 40/1. The mean spontaneous lysis was between 156 and 668 and maximal release between 506 and 2143.
Clinical outcome of SHIV 89.6 P challenge in vaccinated animals: viral loads in plasma. Viral loads in the four vaccinated animals after challenge with SHIV 89.6 P were quantified by monitoring viral RNA, presence of infectious cells in PBMCs, and virus recovery from CD8-depleted PBMCs and lymph node cells. Virus RNA was detected in plasma of all four animals. The peak viral loads in plasma were 230, 5700, 62,000, and 3100 copy Eq/ml in macaque RJo, RPz, RWg, and RTt, respectively. Similar to the control animals, the peak viral burden was observed 2 weeks after challenge. No infectivity was detected in PBMCs of the animals. It is thus possible that either the virus was replicating in cells other than PBMCs or that the infectious cell assay system was not sensitive enough to detect the low levels of virus replication. Viral RNA in plasma became undetectable in two of the four vaccinates (RJo and RPz) by Week 4. These animals remained virus-negative throughout the observation period of over 85 weeks. The two other vaccinated animals followed a slightly different course of infection. Macaque RTt showed peak viral burden of 3100 copy Eq/ml. In the following weeks, the viral burden in this animal ranged between 100 and 1000 copies of viral RNA/ml of plasma until Week 52, when the virus load declined below the level of detection (100 copies Eq/ml plasma). However, at Week 77, when the last real-time RT-PCR analysis was performed, the viral RNA load in this animal was 630 RNA copies Eq/ml. The fourth vaccinated animal (RWg) was the least protected in terms of intensity of virus replication. The virus continued to rep-FIG. 2. CTL activities of PBMC and lymph node effectors against HIV-1Env, SIV-Gag, and SIV-Pol proteins. The PBMC and lymph node cells were obtained 19 weeks after the third vaccine inoculation and the CTL effectors were prepared by stimulating them with UV-irradiated autologous HS CD4 ϩ T-cell clones infected with vaccine-II as described under Materials and Methods. The growing effectors were tested against autologous B-LCL targets infected with wild-type vaccinia virus (‚-‚), and recombinant vaccinia viruses expressing HIV-1ENV (s-s), SIV-GAG (OE-OE), and SIV-POL (ⅷ-ⅷ). The effectors were tested in a 4-h chromium release assay at E/T ratio of 80/1, 40/1, 20/1, and 10/1. The mean spontaneous lysis in these experiments was between 153 and 650 and the mean maximal release was between 587 and 2565.
licate at a low level (2100-29,000 copy Eq/ml) until Week 69 postchallenge. However viral RNA was no longer detectable in plasma of this animal beyond this point (Fig. 4B ).
Virus recovery from PBMCs and lymph nodes
Several experiments involving cocultivation of 10 6 PBMCs of the four challenged vaccinates with indicator C8166 cells failed to result in rescue of infectious virus. However, virus was recovered from PBMCs of two of the animals after depletion of CD8 ϩ T cells from the cell suspensions. The virus rescue attempts were performed using PBMC at Weeks 6, 16, 50, and 82 and lymph node cells at Weeks 50 and 82. At Week 6, only two (RWg and RTt) of the four animals yielded infectious virus from CD8-depleted cells. These results corroborated real-time RT-PCR results that showed a low concentration of viral RNA in plasma of only these two animals. These results also suggested an important role for the CD8 Persistence of challenge virus-specific DNA in PBMC and lymph nodes
In the next series of experiments, we sought to determine whether viral DNA persisted in PBMCs and lymph nodes at different time points after challenge. The results of these experiments are shown in Fig. 5 . The SHIV 89.6 P DNA was present in PBMCs of all four animals 1 week after challenge. At Week 50 only two animals (RWg and RTt) had detectable viral DNA of this virus in PBMCs. However, at this time three of the four animals (RWg, RPz, and RTt) had detectable challenge virus-specific DNA in peripheral lymph nodes. At Week 85 only RWg and RTt had detectable SHIV 89.6 P-specific DNA in PBMCs and lymph nodes.
After challenge with SHIV 89.6 P, the vaccinated animals were also monitored for levels of CD4 ϩ T cells in blood. Results of these experiments are shown in Fig. 4A . All four animals showed a transient decrease in the levels of CD4 ϩ T cells soon after challenge, but cell counts recovered to normal levels in three animals within 5 weeks. As expected, macaque RWg showed relatively more pronounced CD4 ϩ T-cell loss, which was attributed to a higher level of virus replication compared to that of other animals.
Immune responses in vaccinated and control macaques after challenge with SHIV 89.6 P: humoral immune response All four vaccinated animals developed anamnestic neutralizing antibodies to vaccine-I virus during the first 8 weeks following challenge. The neutralizing-antibody titers to this virus were maintained in all four vaccinated animals throughout the observation period. None of the four vaccinates developed detectable neutralizing antibodies against vaccine-II virus but all four developed neutralizing antibodies to SHIV 89.6 P. These became detectable within 4 to 8 weeks after challenge. The anti-
FIG. 3. CD4
ϩ T-cell profile (A), cell-associated virus load (B), and plasma viral load (C) in the three unvaccinated control monkeys inoculated with SHIV 89.6 P. The CD4 profile was determined by a whole blood lysis technique as described under Materials and Methods. The cellassociated virus load is shown as number of infectious cells/10 6 PBMC and determined by infectious cell assay. The viral RNA load in plasma was determined by real-time RT-PCR. body levels increased gradually and achieved peak levels between Weeks 32 and 62 postchallenge. The SHIV 89.6 P-specific neutralizing antibodies persisted throughout the 85-week observation period ( Table 2) .
The two control animals (49/P1 and 49/P2) that developed disease within 7 months did not produce any neutralizing antibodies to SHIV 89.6 P. The third control animal (52/C) produced significant amounts of neutralizing antibodies that were first detectable about 6 months postchallenge. The antibodies persisted until the animal died with AIDS (Table 3) .
Vaccinated animals developed increased CTL activity after challenge with SHIV 89.6 P The unvaccinated animals did not develop any CTLs against SHIV 89.6 P when tested 12 weeks after inoculation with SHIV 89.6 P. PBMCs from the third control animal (52/C) that developed a chronic disease course also failed to develop CTLs when examined at Weeks 24 and 52 (data not shown). The PBMC effectors from four vaccinated animals were tested at four time points for their cytotoxic potential, starting from 12 weeks after challenge with SHIV 89.6 P. At Week 12 postchallenge, cells from three of the four animals caused increased lysis (E/T ratio of 40/1, Fig. 6 ) when compared to that obtained before challenge (Figs. 1 and 2) . The postchallenge CTL responses of macaques RJo and RPz were directed predominantly to the Gag protein, with decreasing activity against Pol and Env, respectively. The fourth macaque, RWg, did not develop any significant increase in virusspecific CTL activity after challenge. Interestingly, this was the only macaque that was found to harbor virus in the lymph nodes, 1 year postchallenge. Macaques RJo and RPz, that had developed the most potent prechallenge CTLs and showed increased activity after challenge, did not have detectable challenge virus DNA in PBMC and lymph nodes. Note that increased CTL-mediated lysis was not considered as anamnestic because of in vitro manipulation of these cells. However, reduced lysis by RWg effectors might have been responsible for the least protection in this animal. Subsequently, all four animals developed CTL activity against Env, Gag, and Pol proteins and these activities were maintained throughout the remainder of the observation period. We also included Nef protein as a target at Weeks 52 and 77 postchallenge. All four animals showed significant lysis against Nef (Table 4) .
Vaccine-induced CTLs were CD8 ϩ T cells and MHC restricted
Vaccine-induced CTLs were characterized by testing for CTL activity in CD4
ϩ and CD8 ϩ T-cell populations
and plasma viral load (B) in four vaccinated animals immunized sequentially with vaccine-I, followed by vaccine-II, and challenged with SHIV 89.6 P. The CD4 profile was determined by a whole blood lysis technique and the viral RNA load in plasma by real-time RT-PCR as described under Materials and Methods. against syngenic and allogenic targets. Unfractionated PBMCs and positively selected CD4 ϩ and CD8 ϩ T cells from vaccinated macaques were cocultured with irradiated autologous HS CD4 ϩ T cells infected with SHIV 89.6 P. After 2 weeks of culture, the three cell populations were used as effectors in the chromium-release assay and tested against autologous CD4 ϩ T cells infected with SHIV 89.6 P. Unfractionated PBMC effectors were also tested against allogenic targets infected with SHIV 89.6 P. A CD4 ϩ T-cell clone from another rhesus macaque was used as the allogenic target. The results of this experiment are shown in Fig. 7 . The effectors from all four macaques recognized and lysed autologous targets infected with SHIV 89.6 P but not the allogenic targets infected with the same virus, indicating that CTL activity was MHC restricted. The CD8 ϩ , but not the CD4 ϩ , T-cell fraction from PBMCs, when used as effectors, exhibited CTL activity. This suggested that the CTLs developed by these vaccinated animals were CD8 ϩ T cells (Fig. 7) .
DISCUSSION
In our earlier studies, we showed that vaccine-II but not vaccine-I conferred long-lasting protection against SHIV-induced AIDS (Joag et al., 1998a; Silverstein et al., 2000) . However, the protective efficacy of vaccine-II was associated with productive infection, albeit transiently, in PBMCs. This was considered a potential for becoming pathogenic. In the present study, the central question was whether the vaccinated animals could benefit from the immunization with vaccine-II in the absence of (potentially dangerous) productive infection by the virus. Therefore, we adopted a new immunization strategy consisting of immunization first with the more-attenuated virus (vaccine-I) followed by immunization with a lessattenuated virus (vaccine-II), hoping that vaccine-I-induced immune responses would suppress the replication of vaccine-II virus. The study showed clearly that all four of the sequentially immunized animals failed to develop infectious cells among their PBMCs following exposure to vaccine-II. However, we could not rule out a low level of replication that was not detectable by infectious cell assays. The doubly immunized animals developed CTLs, but (as expected) no neutralizing antibodies to the heterologous challenge virus. This was the state of their immunity when at 30 weeks after the last exposure to vaccine, the animals were challenged iv with a high dose of SHIV 89.6 P. These animals became infected with the challenge virus, but concentrations of the latter decreased progressively with time and became undetect- 
FIG. 5. PCR analyses of the viral sequences present in
PBMCs and lymph nodes of the four animals that were immunized with vaccine-I, followed by vaccine-II, and challenged with SHIV 89.6 P. The 0.5-g DNA samples were amplified in seminested PCR using SHIV 89.6 P env-specific primers. The primers were specific for SHIV 89.6 P env as they did not amplify vaccine env in a separate reaction. able in three of four vaccinates. The mechanism of protection in this study may be attributed to the presence of CTL precursors at the time of exposure to the challenge virus, rather than neutralizing antibodies, since these did not develop until after the challenge virus had been brought under control. Since vaccine-I had not induced protective immunity in the earlier study (Joag et al., 1998a) , the protection observed in the present study was attributed to the boosting effect of vaccine-II that conferred the long-lasting protection, and this without productive infection in PBMCs.
The availability of HS-immortalized autologous CD4 ϩ T cells, in addition to the more traditional approach using recombinant vaccinia virus-infected B-LCLs for use as targets in CTL assays, added relevance to the clinical interpretation of the results. CD4 ϩ T cells are one of the main targets of the pathogenic virus and, when used as targets after infection with vaccine and challenge viruses, extended the range of interpretation of the CTL assays. In view of the high rate of mutation in lentiviruses during infection, and the presence of different quasispecies of the virus, B cells cannot serve as efficient targets for detection of CTL responses, except where CTL epitopes are highly conserved. Since HS-immortalized CD4 ϩ T cells can be infected with different viral quasispecies, they have been successfully used as targets in cytotoxicity assays against constantly evolving immune escape viruses (Stipp et al., 2000) . In this study, all four animals that were immunized with vaccine virus had developed CTLs to vaccine and challenge viruses prior to challenge. These CTLs in three of these animals recognized the three structural lentiviral proteins, Env, Gag, and Pol, but in one animal, RWg, they recognized only Env, not Gag and Pol proteins. Following challenge with SHIV 89.6 P, this animal developed CTL activity against FIG. 6. Postchallenge CTL activity of the vaccinated macaques against SHIV 89.6 P, HIV-1ENV, SIV-GAG, and SIV-POL. PBMCs from the four vaccinated macaques, obtained 12 weeks after challenge with pathogenic virus SHIV 89.6 P, were stimulated twice with UV-irradiated autologous HS CD4 ϩ T-cell clones infected with SHIV 89.6 P. Two weeks after the first stimulation, growing cells were used as CTL effectors and tested against autologous HS CD4 all three proteins, albeit at a low level. The low reactivity to Gag and Pol proteins could have been responsible for the relatively higher level of virus replication in this animal compared to that of the other vaccinates.
Our results also showed that the lymph node CTLs had a broader range and a higher magnitude of specific lysis compared to that of the CTLs in PBMCs. This suggested that measurement of CTL activity in the lymph nodes was a more accurate correlate of resistance of the immunized animals to the virus. Comparison of PBMC and lymph node CTLs is not a common practice. However, in a recent study in SIV-infected macaques, PBMCs and lymph nodes showed almost similar patterns of CTL activity (Kuroda et al., 1999) . The reason for the different specificity of the CTLs in the two compartments of the immune system in this study is not yet known, although it might be attributed to different precursor frequencies in the blood and lymph nodes.
This study suggested that neutralizing antibodies might have had a lesser role than CTLs in controlling replication of the challenge virus. Vaccine-induced antibodies neutralized vaccine-I virus but did not neutralize vaccine-II. This might be attributed to the fact that vaccine-I and vaccine-II Env sequences differed in 2.3% amino acids, variations that might be critical in expression of neutralization epitopes. The challenge virus SHIV 89.6 P Env has 16.7% sequence variation compared to that of vaccine-I and 18.1% with vaccine-II; therefore, vaccine-induced neutralizing antibodies could not neutralize SHIV 89.6 P. The neutralizing-antibody responses to the challenge virus apparently developed only after productive infection of the latter; thus, they could not have had a role in controlling the initial infection by the challenge virus. However, whether these antibodies had a role in subsequent elimination of the virus is open to speculation. Earlier studies in several laboratories including ours showed that passive immunization with neutralizing antibodies could prevent infection with virus given later, but the antibodies had no effect on early containment of the virus when administered after inoculation of the virus (Foresman et al., 1998; Shibata et al., 1999; Mascola et al., 1999; Binley et al., 2000) . The longterm effects of passive immunization on SHIV pathogenesis are not known. It is possible that the combined effect of the antibodies that emerged following challenge with SHIV 89.6 P and the CTLs may have been responsible for clearing virus in the challenged animals in the present study.
This study also confirms earlier observations that development of protective antibodies is time dependent and associated with a complex and lengthy maturation of immune responses over the first 6 to 8 months postinoculation. During this time period, envelope-specific antibody responses undergo an evolution in quantitative and qualitative properties systems. The completed maturation of immune responses is then characterized by relatively steady-state antibody responses that are maintained indefinitely (Clements et al., 1995; Cole et al., 1997a Cole et al., ,b, 1998 Montelaro et al., 1998) . After immunization, vaccine-I-and vaccine-II-specific antibodies required a PBMC effectors from different animals were tested against different targets at Effector/Target ratio of 80/1, 40/1, 20/1, and 10/1. The results shown here are specific lysis obtained at Effector/Target ratio of 40/1. The spontaneous counts in these experiments ranged between 187 and 210 and maximal counts ranged between 1473 and 1815.
b Specific lysis against control targets represents either uninfected autologous CD4 ϩ T-cell clone or autologous B-LCLs infected with wild type vaccinia virus and used as targets in 4-h chromium release assay.
c Autologous CD4 ϩ T-cell clones were infected with SHIV 89.6 P virus for 3 days, labeled with [ 51 Cr] and used in cytotoxicity assays. d Autologous B-LCLs were infected overnight with recombinant vaccinia virus expressing either HIV Env , SIV Gag , SIV Pol , or SIV Nef and used as targets. e Not done. about 9 months before they attained peak levels and then maintained at steady levels. Likewise, after challenge, SHIV 89.6 P-specific antibodies were produced but again they required more than 8 months before achieving peak levels. In a previously reported study, live attenuated SIV has been found to induce SIV-specific antibodies that directly correlated with the level of protection after challenge with pathogenic SIV MAC 251 and inversely correlated with the level of attenuation of vaccine virus .
The findings in this report not only clearly suggest that significant protection can be achieved in the absence of challenge virus-specific neutralizing antibodies but also support a growing consensus that virus-specific CTLs are one of the most important effector mechanisms responsible for suppression of virus replication in HIV-1-infected individuals and in SIV-or SHIV-infected experimental animals (Harrer et al., 1996; McMichael and O'Callaghan, 1998; Ogg et al., 1998; Johnson and Desrosiers, 1998; Wyand et al., 1999; Johnson et al., 1999) . The seminal role of these cells in regulating pathogenesis was previously well established in SIV-infected macaques, in which their depletion resulted in higher virus burdens (Schmitz et al., 1999; Jin et al., 1999) . The results described in this report also focus attention on CTLs to Gag and Pol for controlling SHIV infection. The vaccine virus used in the study was derived from nonpathogenic SHIV that contained the HIV-1 envelope from HXB2 isolate, while challenge virus SHIV 89.6 P contained the envelope of HIV-1 89.6 . Our results that the live attenuated vaccines used in this study conferred substantial protection against virus SHIV 89.6 P, a virus that contains distinct env but common gag and pol genes, suggest that protection, mediated through CTLs against the Gag and Pol proteins, was common between the two viruses.
In summary, a graded course of immunization, first with more attenuated virus followed by relatively less attenuated virus may be a way to reduce the replication of highly effective vaccine viruses and thus reduce the chances of reversion of vaccine virus into a pathogenic strain. The safer sequential vaccination procedure induced long-term protection against AIDS caused by heterologous virus. The results in the present study provide evidence for the apparent lack of correlation between antibody and protection in vaccinated animals, significantly reduced virus replication (200-to 60,000-fold) in vaccinated group compared to that in control animals, and positive correlation between virus-specific CTLs and protection. Whether these protected animals develop progressive decline of challenge virus DNA as seen in animals immunized with vaccine-II alone (Silverstein et FIG. 7 . SHIV 89.6 P-specific CTL activity in macaques immunized with vaccine-I, followed by vaccine-II, and challenged with SHIV 89.6 P was MHC restricted and mediated by CD8 ϩ T lymphocytes. PBMCs from the four vaccinated macaques, obtained 12 weeks after challenge with pathogenic virus SHIV 89.6 P, were stimulated twice with UV-irradiated autologous HS CD4 ϩ T-cell clones infected with SHIV 89.6 P. Two weeks after the first stimulation, growing cells were used as CTL effectors and tested against autologous and allogenic HS CD4 ϩ T-cell clones infected with SHIV 89.6 P. A HS CD4 ϩ T-cell clone from another rhesus macaque was used as an allo-target. Positively selected CD4 ϩ and CD8 ϩ T cells were stimulated with SHIV 89.6 P as described above and used as CTL effectors in a 4-h chromium release assay against autologous HS CD4 ϩ T-cell clones infected with SHIV 89.6 P. The results shown here are specific lysis obtained at an effector/target ratio of 40/1. The mean spontaneous lysis was between 109 and 475 and mean maximal lysis between 610 and 2570.
al., 2000) will be determined in follow-up studies in these animals.
MATERIALS AND METHODS
Viruses
Constructions of vaccine-I and vaccine-II (Joag et al., 1998a) viruses and derivation of and SHIV KU-2 (Joag et al., 1998b) were previously described. These viruses were grown in CEMx174 cells. The challenge virus SHIV 89.6 P (Reimann et al., 1996a,b) was kindly provided by Dr. Norman L. Letvin (Boston, MA) and grown in PHA-stimulated PBMC from a normal healthy monkey. Infectivity of stocks of the four viruses was assayed in C8166 cell culture and titers of log 4.2, 4, 4.8, and 4.0 were obtained for vaccine-I, vaccine-II, SHIV KU-2 , and SHIV 89.6 P, respectively. Herpesvirus papio stock was obtained by growing the S594 cell line (provided by Dr. N. Letvin). The S594 cell line is an immortalized B-cell line productively infected with the baboon Herpesvirus papio (Rabin et al., 1977) . Herpesvirus saimiri was purchased from ATCC (Manassas, VA) and stock cultures were prepared by inoculating monolayer cultures of owl monkey kidney (OMK) cells as previously described (Kumar et al., 1999) . The recombinant vaccinia viruses that were used to infect target cells included vAbT299 (expressing HIV-1 BH-10 Env lacking 19 amino acids, starting from positions 42-60 at the amino terminus), vAbT252 (SIV mac 251-Gag), vAbT258R (SIV mac 251-Pol), vAbT306 (SIV mac 239-Nef), and NYCBH (wild type vaccinia virus). These were kindly provided by Drs. D. Panicali and G. Mazzara (Therion Biologics, Cambridge, MA). The recombinant vaccinia viruses were propagated in HeLa cell cultures. All virus stocks were maintained at Ϫ80°C, except the challenge virus stocks that were stored in liquid nitrogen.
Vaccination of macaques and challenge with SHIV 89.6 P Seven 3-to 5-year-old rhesus macaques (Macaca mulatta) were obtained from the Yerkes Primate Center (Atlanta, GA) and maintained in the AAALAC-approved Animal Facility of the University of Kansas Medical Center. Four of the animals were inoculated subcutaneously, close to the inguinal and axillary lymph nodes, with 1 ml of vaccine-I. Four months later, these four animals received two doses of 1 ml of vaccine-II, given orally 1 day apart. Since vaccine-I virus was T-cell-tropic, it was administered by subcutaneous route. The vaccine-II is dual tropic and was administered by oral route (results not shown). Three months following this, the animals were given a booster dose of vaccine-II. Thirty weeks after the third immunization, the vaccinated and three unvaccinated control animals were challenged iv with 1 ml of undiluted SHIV 89.6 P (10 4 TCID 50 ) stock. These animals were bled regularly to monitor CD4 ϩ T-cell profiles, cellassociated as well as cell-free viral loads in the blood, and cellular and humoral immune responses to the different viruses.
Flow cytometry
Leukocytes in whole blood collected in EDTA were analyzed for expression of CD3, CD4, and CD8 cell surface markers by whole blood lysis technique as previously described . Briefly, 20 l of antibody mix against CD3, CD4, and CD8 (Becton-Dickinson, Rutherford, NJ) was added to 100 l of whole blood and incubated for 30 min in the dark. Lysing solution (Becton-Dickinson) was then added and the samples were incubated for another 10 min at room temperature. Stained cells were fixed with 0.5% paraformaldehyde and analyzed in a flow cytometer (BectonDickinson FACS Calibur).
Viral load measurements
Plasma viral RNA levels were determined by real-time reverse transcriptase-PCR (ABI Prism 7700-sequence detection system; Perkin-Elmer, Palo Alto, CA) using reverse-transcribed viral RNA from macaque plasma samples as templates. Primer sequence and the procedures for RNA extraction, reverse transcription, and PCR were previously described (Suryanarayana et al., 1998) . The sensitivity of this assay was 100 copies Eq/ml of plasma. The frequency of infectious cells in blood was determined by inoculation of serial 10-fold dilutions of PBMC into cultures of C8166 cells that were then observed for the development of cytopathic effects (CPE) (Joag et al., 1998a) . Results are expressed as the number of infectious cells per 10 6 PBMC.
Recovery of infectious virus from PBMCs and lymph node cells
Two million CD8-depleted PBMCs or lymph node cells were stimulated with PHA (1 g/ml) for 2 days in 2 ml R-10 (RPMI 1640 containing 10% FBS, 5 mM NaHCO 3 , and 50 g/ml gentamicin), after which they were washed and cultured in R-10/IL-2 (R-10 containing 50 IU/ml recombinant interleukin 2) for 5 days. The supernatant fluids were tested for virus cytopathocity in C8166 culture.
Detection of viral DNA in PBMC and lymph nodes Cellular DNA was extracted from PBMCs and lymph nodes of the four vaccinated animals and used as a template in nested PCR as previously described (Joag et al., 1998a) . Pathogenic virus was detected by amplification of the SHIV 89.6 P-specific envelope. For the first round of PCR amplification, we used ES361 (5Ј-GATAGACTA-ATAGAAAGAGCAGAAGAC-3Ј) and SM-1 (5Ј-GATGAA-CATCTAATTTGTCCTG-3Ј, antisense), which are complementary to nts 6305 to 6331 and 7647 to 7669 of the SHIV 89.6 P genome. A 0.5-g sample of genomic DNA was used in the 50-l reaction mixture and amplified for 40 cycles in a hot-start PCR. The reaction conditions were: 97°C for 1 min 45 s, 55°C for 2 min, and 72°C for 5 min for one cycle; 94°C for 30 s, 55°C for 30 s, and 72°C for 90 s for 38 cycles; and 94°C for 30 s, 55°C for 30 s, and 72°C for 6 min for one cycle. A 2-l aliquot of the first-round PCR product was again amplified using SM-2 (5Ј-7168 CTGAAGATTTCACAGACAATGT 7169 -3Ј) and SM-1 primers. The expected size of the nested PCR product was 501 bp. A 5-l aliquot of the second-round PCR product was electrophoresed in a 2% agarose gel and stained with ethidium bromide for visualization. This assay is capable of detecting one viral genome in approximately 10 4 cells.
Determination of binding antibodies against vaccine and challenge viruses
Sequentially collected plasma samples from vaccinated macaques were analyzed for the presence of binding antibodies to native viral glycoprotein using Con A ELISA originally developed by Robinson and coworkers (1990) and adapted to the SIV and SHIV systems by Montelaro and coworkers (Cole et al., 1997a (Cole et al., ,b, 1998 . Briefly, purified virus was treated with Triton X-100 and used as viral antigens. Immulon-2 plates were coated with Con A followed by the addition of total viral proteins. The reactivity was detected by the addition of 1/10,000 dilution of HRP-labeled anti-monkey IgG followed by reaction with ortho-phenylinediamine (OPD).
Determination of neutralizing antibodies against vaccine viruses
Neutralizing antibody titers in the plasma were determined by adding serial twofold dilutions of heat-inactivated plasma, prepared in R-10 to flat-bottom 96-well plates, using four wells per dilution. Eight TCID 50 of vaccine-I, vaccine-II, or SHIV 89.6 P viruses were then added to each well and the plates were incubated at 37°C for 1 h, followed by addition of 10 4 C8166 cells to each well. After 1 week of incubation at 37°C, each well was scored for CPE .
Development of B-lymphoblastoid cell line (B-LCL)
The B-lymphoblastoid cell lines (B-LCLs) were derived by inoculating PBMCs with Herpesvirus papio and maintaining the cells for 2 weeks in the presence of 500 ng/ml of cyclosporin-A (Sigma, St. Louis, MO) in 200 l of R-10. Proliferating cells were transferred to tissue culture flasks and maintained in R-10 throughout the study .
Development of autologous CD4
ϩ T-cell clones CD4 ϩ T cells from all animals were immortalized by infection with Herpesvirus saimiri. Briefly, CD8-depleted PBMCs were inoculated with Herpesvirus saimiri and maintained in R-10/IL-2 for 1 week. The cells were then cloned by the limiting dilution method, using irradiated human PBMCs as feeders. Proliferating clones were cultured in R-10/IL-2 and characterized by the expression of the CD4 cell surface marker (Kumar et al., 1999) .
Generation of effector T-cell populations and CTL assays
Effectors for the CTL assays were obtained by coculturing PBMCs from vaccinated and control macaques with UV-irradiated, autologous Herpesvirus saimiri-immortalized CD4
ϩ T cells (HS-CD4 ϩ T cells) infected with either vaccine-II virus or SHIV 89.6 P as previously described (Kumar et al., 1999) . After 3 days, the medium was supplemented with recombinant interleukin 2 (rIL-2). On Day 7, growing PBMCs were restimulated with similar stimulators and maintained in R-10/IL-2. These effectors were used in chromium-release assays 6-9 days after restimulation and tested against virus-infected targets and recombinant vaccinia virus-infected targets. Autologous HS-CD4 ϩ T cells infected with either SHIV KU-2 or SHIV 89.6 P were infected for 3 days and used as virusspecific targets. In a typical experiment 50-70% of the CD4 ϩ T cells were infected with different viruses (results not shown). Autologous B-LCLs were infected overnight with recombinant vaccinia viruses expressing HIV-1Env, SIV-Gag, SIV-Pol, or SIV-Nef and used as targets in chromium-release assays.
Target cells, labeled with 100 Ci 51 Cr [spec. act. 962 MBq/ml of sodium chromate; (Amersham, Cleveland, OH)], were dispensed into 96-well V-bottom plates, and effector cells were tested in triplicate at effector/target (E/T) ratios of 80/1, 40/1, 20/1, 10/1, and 5/1. Chromium release was determined after a 4-h incubation at 37°C by counting 100 l supernatant from each well in a Gamma counter (Packard Instruments, Meriden, CT). Each experiment had three wells containing 2500 respective targets in medium that provided data for spontaneous lysis, while three wells containing targets and 100 l of 1% SDS provided data for maximal lysis. The percentage specific lysis was calculated as: (mean CPM in test wells Ϫ mean CPM in spontaneous wells)/(mean CPM in maximal wells Ϫ mean CPM in spontaneous wells) ϫ 100.
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